{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:15:08Z","timestamp":1788023708618,"version":"build-2784847793"},"reference-count":16,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jid.2018.01.041","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T21:17:29Z","timestamp":1521753449000},"page":"1955-1961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Evaluation of sPGA\u00a0\u00d7 BSA as an Outcome Measure and Treatment Target for Clinical\u00a0Practice"],"prefix":"10.1016","volume":"138","author":[{"given":"Joseph F.","family":"Merola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoungah","family":"See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel","family":"Burge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Mallinckrodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement K.","family":"Ojeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2018.01.041_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.01.041_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/ard.2010.128462","article-title":"\u2018Treat to target\u2019: moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis","volume":"69","author":"Atar","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2018.01.041_bib3","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1056\/NEJMp1311957","article-title":"Medicare\u2019s physician value-based payment modifier\u2014will the tectonic shift create waves?","volume":"369","author":"Chien","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2018.01.041_bib4","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/jdv.13132","article-title":"Comparison of three methods for measuring psoriasis severity in clinical studies (part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician\u2019s Global Assessment and Lattice System Physician\u2019s Global Assessment","volume":"29","author":"Chow","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2018.01.041_bib5","first-page":"147","article-title":"Evaluation of the Physician Global Assessement and Body Surface Area composite tool for assessing psoriasis response to apremilast therapy: results from ESTEEM 1 and ESTEEM 2","volume":"16","author":"Duffin","year":"2017","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"Suppl. 2","key":"10.1016\/j.jid.2018.01.041_bib6","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2018.01.041_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1016\/j.jid.2018.01.041_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2018.01.041_bib9","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/jid.2012.124","article-title":"Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis","volume":"132","author":"Gourraud","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2018.01.041_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2018.01.041_bib11","doi-asserted-by":"crossref","first-page":"A122","DOI":"10.1016\/j.jval.2016.03.490","article-title":"Assessing severity in psoriasis: correlation of different measures (PASI, BSA, and IGA) in a Canadian real-word setting","volume":"19","author":"Lane","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.jid.2018.01.041_bib12","unstructured":"National Institute for Health and Care Excellence. Psoriasis: assessment and management, clinical guideline [CG153], https:\/\/www.nice.org.uk\/guidance\/cg153; 2012 (accessed 11 August 2017)."},{"key":"10.1016\/j.jid.2018.01.041_bib13","first-page":"770","article-title":"International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: meeting summary and data from the Psoriasis Working Group","volume":"16","author":"Perez-Chada","year":"2017","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jid.2018.01.041_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","article-title":"The Psoriasis Area and Severity Index is the adequate criterion to define severity in chronic plaque-type psoriasis","volume":"210","author":"Schmitt","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2018.01.041_bib15","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/1471-2474-14-350","article-title":"Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry","volume":"14","author":"Vermeer","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jid.2018.01.041_bib16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jaad.2013.07.040","article-title":"Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort","volume":"69","author":"Walsh","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X1831741X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X1831741X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T22:55:43Z","timestamp":1751496943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X1831741X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0022202X1831741X"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2018.01.041","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of sPGA\u00a0\u00d7 BSA as an Outcome Measure and Treatment Target for Clinical\u00a0Practice","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2018.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Eli Lilly and Company. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}